Senhwa reports Phase I data for CX-5461 in hematologic malignancies

Senhwa Biosciences Inc. (TPEx:6492) reported data from 16 evaluable patients with advanced hematologic malignancies in a dose-escalation Phase I trial showing that IV CX-5461 led to one partial response in a patient with anaplastic large cell lymphoma and five cases of stable disease in patients with multiple myeloma (MM) or diffuse large B cell lymphoma (DLBCL). The maximum tolerated dose (MTD) was 170 mg/m² CX-5461 every 21 days. CX-5461 was well tolerated. Data were presented at the American Society of Hematology meeting in Atlanta in December 2017. The trial was conducted in collaboration with the Peter MacCallum Cancer Centre.

Senhwa plans to start a Phase II trial of CX-5461 to treat MM this year. The company is also conducting a Phase I/II trial of CX-5461 to treat breast cancer that is expected to complete by year end...